A Phase I Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function.

Trial Profile

A Phase I Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2012

At a glance

  • Drugs Oblimersen (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Mar 2012 Actual end date (September 2009) added as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 May 2007 to 1 Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top